本帖最后由 老马 于 2012-1-13 21:20 编辑 " x0 S3 V& z& L; D$ O9 Z
% i2 [. A, C& e }; q' z( I8 [
爱必妥和阿瓦斯丁的比较+ i$ H( }2 D/ }
2 N! F, ^& I/ ^* _2 T9 {% ]3 |http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 T2 j q T( N- ^7 D: C/ I8 d% k
. t( Y3 F% B& k+ R
; K1 _) ?5 U( j! o4 w5 {http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
" d' n- E( d. w/ j3 |! {==================================================0 o, P2 e9 y; Z* a, |* y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% }( \; ?2 w! `" M& uPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
( t8 D' K4 U+ w* H8 w, BResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.! E" i1 W9 t5 _+ W' W& d
|